Recent share performance and company snapshot
Charles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the past 3 months, prompting closer attention from investors.
The US based contract research company, which supports drug discovery and safety testing across pharmaceuticals and biotech, currently has a market value of about US$7.3b and last closed at US$149.93 per share.
See our latest analysis for Charles River Laboratories International.
Against this backdrop, the 1-year total shareholder return of 6.05% contrasts with the share price weakness. The stock has retreated sharply in recent weeks and broader momentum has faded.
If this shift in sentiment has you reassessing your opportunities in healthcare and biotech, it could be a good moment to scan for other specialist growth stories through our 31 healthcare AI stocks
With Charles River Laboratories International down sharply in recent months but showing a 1 year total return of 6.05%, investors may be asking whether this recent weakness indicates an undervalued entry point or if the current price already reflects expectations for future growth.
Most Popular Narrative: 52.2% Undervalued
According to the most followed narrative, Charles River Laboratories International’s fair value of $313.61 sits well above the last close of $149.93, which is driving fresh interest in the stock’s long term setup.
The deal effectively expands and secures access to NHP supply, highlighting how critical primate availability has become in modern drug development. In other words, this acquisition reveals one of the hidden bottlenecks in the pharmaceutical research ecosystem: the supply of non-human primates.
Curious what kind of growth path and profitability shift would justify more than doubling today’s price? The narrative leans heavily on earnings inflection, improving margins and a future valuation multiple usually reserved for higher growth healthcare leaders.
Result: Fair Value of $313.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this bullish setup still faces risks, including regulatory scrutiny around primate sourcing and the company’s recent multi year total returns, which may curb confidence in a rerating.
Find out about the key risks to this Charles River Laboratories International narrative.
Another view: DCF sends a very different signal
While the user narrative sees fair value at $313.61 and labels the stock undervalued, our DCF model points the other way, with an estimated value of $78.12 per share versus the current $149.93. That gap frames a simple question for you: which story do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With such a strong split between bullish and cautious views, you may want to act promptly and review the full picture yourself by weighing 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If CRL has sparked fresh thinking about your portfolio, do not stop here; the next step is comparing it with other stocks that offer different risk and return profiles.
- Target potential value opportunities by reviewing companies in the 52 high quality undervalued stocks that some investors may be overlooking.
- Prioritise resilience by scanning stocks in the 65 resilient stocks with low risk scores if you want steadier profiles and lower risk scores.
- Spot earlier stage opportunities by checking the 29 elite penny stocks with strong financials that already show stronger financial foundations than many peers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com